Associations of metabolic disorders with hypertension and cardiovascular disease: recent findings and therapeutic perspectives
A Tanaka, K Node - Hypertension Research, 2024 - nature.com
We theoretically know that metabolic disorders, including overweight/obesity, insulin
resistance, diabetes, dyslipidemia, and relevant tissue/organ damage, play a critical role in …
resistance, diabetes, dyslipidemia, and relevant tissue/organ damage, play a critical role in …
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
K Chatzianagnostou, M Gaggini… - International Journal of …, 2024 - mdpi.com
Although good glycemic control in patients with type 2 diabetes (T2D) can prevent
cardiovascular complications, many diabetic patients still have poor optimal control. A new …
cardiovascular complications, many diabetic patients still have poor optimal control. A new …
Degradation of the α-Carboxyl Terminus 11 Peptide: In Vivo and Ex Vivo Impacts of Time, Temperature, Inhibitors, and Gender in Rat
Y Tasdemiroglu, MA Council-Troche… - ACS Pharmacology & …, 2024 - ACS Publications
In previous research, a synthetic α-carboxyl terminus 1 (αCT1) peptide derived from
connexin 43 (Cx43) and its variant (αCT11) showed beneficial effects in an ex vivo ischemia …
connexin 43 (Cx43) and its variant (αCT11) showed beneficial effects in an ex vivo ischemia …
Targeting obesity for therapeutic intervention in heart failure patients
R Sato, S von Haehling - Expert Review of Cardiovascular …, 2024 - Taylor & Francis
Introduction Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous
syndrome, making it challenging to improve prognosis with pharmacotherapy. Obesity is one …
syndrome, making it challenging to improve prognosis with pharmacotherapy. Obesity is one …